{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:00:22Z","timestamp":1781078422569,"version":"3.54.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.msard.2025.106857","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T01:37:28Z","timestamp":1763084248000},"page":"106857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world evaluation of subcutaneous natalizumab in patients with highly active relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-3615","authenticated-orcid":false,"given":"Tarunya","family":"Arun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarmad","family":"Al-Araji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Pye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Shehu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106857_bib0001","series-title":"Summary of Product Characteristics","article-title":"Tysabri 150 mg solution for injection in pre-filled syringe","year":"2025"},{"issue":"1","key":"10.1016\/j.msard.2025.106857_bib0003","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00415-023-11955-0","article-title":"Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study","volume":"271","author":"Filippi","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106857_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241241382","article-title":"Real-world evidence and patient preference for subcutaneous versus intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study","volume":"17","author":"Gold","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106857_bib0005","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/tcrm.2007.3.2.259","article-title":"Natalizumab: a new treatment for relapsing remitting multiple sclerosis","volume":"3","author":"Hutchinson","year":"2007","journal-title":"Ther. Clin. Risk. Manag."},{"issue":"3","key":"10.1016\/j.msard.2025.106857_bib0006","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106857_bib0007","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.msard.2025.106857_bib0008","doi-asserted-by":"crossref","first-page":"e1583","DOI":"10.1002\/wsbm.1583","article-title":"Neurodegeneration in multiple sclerosis","volume":"15","author":"Mey","year":"2023","journal-title":"WIREs. Mech. Dis."},{"issue":"10","key":"10.1016\/j.msard.2025.106857_bib0009","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcph.707","article-title":"A randomized trial evaluating various administration routes of Natalizumab in multiple sclerosis","volume":"56","author":"Plavina","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.msard.2025.106857_bib0010","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2025.106857_bib0011","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2025.106857_bib0012","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3174\/ajnr.A2226","article-title":"Natalizumab (Tysabri)","volume":"31","author":"Selewski","year":"2010","journal-title":"AJNR. Am. J. Neuroradiol."},{"issue":"6","key":"10.1016\/j.msard.2025.106857_bib0013","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s40120-023-00539-9","article-title":"Natalizumab treatment of relapsing remitting multiple sclerosis has No long-term effects on the proportion of circulating regulatory T cells","volume":"12","author":"Tanasescu","year":"2023","journal-title":"Neurol. Ther."},{"issue":"6","key":"10.1016\/j.msard.2025.106857_bib0014","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/jnnp-2022-330467","article-title":"Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis","volume":"94","author":"Toorop","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"issue":"14","key":"10.1016\/j.msard.2025.106857_bib0015","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1177\/13524585211003020","article-title":"A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis","volume":"27","author":"Trojano","year":"2021","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:28:40Z","timestamp":1781076520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":14,"alternative-id":["S2211034825005991"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106857","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evaluation of subcutaneous natalizumab in patients with highly active relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106857"}}